Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier's head of business development outlines how one of France's leading pharma companies is planning for the future amidst a changing geopolitical scene. In 2026, Servier complete
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier's head of business development outlines how one of France's leading pharma companies is planning for the future amidst a changing geopolitical scene. In 2026, Servier completed the $2.5 billion acquisition of the oncology developer Day One Biopharmaceuticals and acquired the muscular dystrophy business of Edgewise Therapeutics for around $2.
65 billion, following major AI-focused deals with InSilico Medicine and Iktos. In this latest episode, Pharmaceutical Technology reporter Frankie Fattorini speaks with the head of business development Frederic Scaerou to understand how these deals are shaping Servier as the French multinational navigates shifting global industry trends. "Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier's head of business development outlines how one of France's leading pharma companies is planning for the future amidst a changing geopolitical scene. In 2026, Servier completed the $2.5 billion acquisition of the oncology developer Day One Biopharmaceuticals and acquired the muscular dystrophy business of Edgewise Therapeutics for around $2.
65 billion, following major AI-focused deals with InSilico Medicine and Iktos. In this latest episode, Pharmaceutical Technology reporter Frankie Fattorini speaks with the head of business development Frederic Scaerou to understand how these deals are shaping Servier as the French multinational navigates shifting global industry trends. "Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier's head of business development outlines how one of France's leading pharma companies is planning for the future amidst a changing geopolitical scene. In 2026, Servier completed the $2.5 billion acquisition of the oncology developer Day One Biopharmaceuticals and acquired the muscular dystrophy business of Edgewise Therapeutics for around $2.
65 billion, following major AI-focused deals with InSilico Medicine and Iktos. In this latest episode, Pharmaceutical Technology reporter Frankie Fattorini speaks with the head of business development Frederic Scaerou to understand how these deals are shaping Servier as the French multinational navigates shifting global industry trends. "Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Đọc thêm từ Tài chính
Europe Diesel Prices Soar as Ukraine Strikes Hit Russian Exports
European diesel prices are soaring as Ukraine keeps up attacks Russian oil refineries, a reminder that supply risks for one of the world’s most crucial fuels extend far beyond the Middle East.
Bond traders are watching this tracker to figure out the real odds of Fed rate hikes
A Fed gauge of wage growth is due to be updated on Friday, followed by a June reading on consumer inflation next Tuesday.